Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Evaluation of efficacy of coenzyme Q10 eye drop in corneal ulcer treatment

Poster Details

First Author: E.Seven TURKEY

Co Author(s):    M. Batur   S. Tekin                 

Abstract Details

Purpose:

We aimed to evaluate effectiveness of coenzyme Q10 (CoQ10) eye drops on healing corneal ulser.

Setting:

Yuzuncu Yil University, Department of Ophthalmology

Methods:

Patients who were hospitalized with diagnosis of corneal ulcer were included in the study. Complete ophthalmologic examination were performed to all patients and recorded presence of hypopyon. Corneal ulcer size was measured. Ulcer localization was recorded. Patients were randomly divided into two groups. Both groups were treated with topical antibiotic and cyclopentolate eye drops. In addition to the first group, CoQ10 eye drops 4 times per day was added to treatment and continued at least 2 weeks or until the ulcer healed. Before and after treatment images of corneal ulcers were taken and recorded daily until the ulcer healed.

Results:

The mean age of the 37 patients included in the study was 49.08 ± 24.42 (7-90) years, 22 (59.46%) were male and 15 (40.54%) were female. There was no statistically significant difference in terms of age, gender, right and left eye involvement, hypopyon presence and corneal ulcer size in CoQ10 eye drop group (n = 20) and control group (n =17) (p> 0.05). The mean healing time was statistically significant between CoQ10 eyedrop group (10.9 ± 6.08 days) and control group (18.53 ± 12.64 days) (p = 0.026). No adverse effects related to the given treatments were observed.

Conclusions:

CoQ10 eye drops can be considered as a new agent in the treatment of corneal ulcers as a supportive agent in terms of shortening of the healing period. However, there is a need for more extensive series, randomized, prospective clinical trials.

Financial Disclosure:

None

Back to Poster listing